×

Research and Markets: Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-Effectiveness Continue to Drive Eylea's Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD)

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/xjnrww/ophthalmology) has announced the addition of the "Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eylea's Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD)" report to their offering.

GBI Research, the leading business intelligence provider, has released its latest research, ""Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eylea's Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD)"", which provides insights into the global ophthalmology therapeutics market, with forecasts until 2018.

The report provides an in-depth analysis of the key therapeutic indications of ophthalmology, namely glaucoma, allergic conjunctivitis, Dry Eye Syndrome (DES), Diabetic Macular Edema (DME), and Wet Age Macular Degeneration (Wet-AMD). The report also examines the ophthalmology therapeutics treatment usage patterns for the covered indications. In addition, the report includes insights into the ophthalmology R&D pipeline.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

In 2011, the global ophthalmology therapeutics market was estimated to be around $10 billion, growing at a Compound Annual Growth Rate (CAGR) of 7.2% between 2004 and 2011. The glaucoma market was the largest segment followed by Wet-AMD. These segments accounted for 36% and 32% of the global ophthalmology therapeutics market in 2011, respectively.

The decline in glaucoma revenue due to significant generic erosion will change the therapeutic landscape until 2018, when glaucoma is expected to account for 23%, a decline of 13% relative to 2011, and the wet-AMD market is expected to account for 37% of the global ophthalmology market, an increase of 5% relative to 2011. The decline in the glaucoma market is expected to be offset by a healthy growth in the wet-AMD, DME, and DES markets. These markets are expected to grow due to the presence of considerable unmet need and increasing treatment-seeking and diagnosis rates.

Scope:

- The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the glaucoma, allergic conjunctivitis, DES, DME, and wet-AMD therapeutics market.

- Data and analysis for the global ophthalmology therapeutics market

- Annualized market data for the ophthalmology therapeutics market from 2004 to 2011, with forecasts to 2018

- Key drivers and restraints that have had a significant impact on the market

- The competitive landscape of the global ophthalmology therapeutics market

- Key M&A activities and licensing agreements that took place in the ophthalmology therapeutics market

Companies Mentioned:

- Allergan, Inc.

- Merck & Co Inc

- Novartis AG

- Pfizer

- Roche

For more information visit http://www.researchandmarkets.com/research/xjnrww/ophthalmology

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Source: Research and Markets